Recent Advances on Drug-Loaded Mesenchymal Stem Cells With Anti-neoplastic Agents for Targeted Treatment of Cancer

Overview

Journal Front Bioeng Biotechnol

Date 2020 Aug 15

PMID 32793565

Citations 45

Authors

Amirhesam Babajani

Pegah Soltani

Elham Jamshidi

Mohammad Hadi Farjoo

Hassan Niknejad

Affiliations

Soon will be listed here.

Abstract

Mesenchymal stem cells (MSCs), as an undifferentiated group of adult multipotent cells, have remarkable antitumor features that bring them up as a novel choice to treat cancers. MSCs are capable of altering the behavior of cells in the tumor microenvironment, inducing an anti-inflammatory effect in tumor cells, inhibiting tumor angiogenesis, and preventing metastasis. Besides, MSCs can induce apoptosis and inhibit the proliferation of tumor cells. The ability of MSCs to be loaded with chemotherapeutic drugs and release them in the site of primary and metastatic neoplasms makes them a preferable choice as targeted drug delivery procedure. Targeted drug delivery minimizes unexpected side effects of chemotherapeutic drugs and improves clinical outcomes. This review focuses on recent advances on innate antineoplastic features of MSCs and the effect of chemotherapeutic drugs on viability, proliferation, and the regenerative capacity of various kinds of MSCs. It also discusses the efficacy and mechanisms of drug loading and releasing procedures along with and preclinical outcomes of antineoplastic effects of primed MSCs for clinical prospection.

Citing Articles

Cold and hot tumors: from molecular mechanisms to targeted therapy.

Wu B, Zhang B, Li B, Wu H, Jiang M Signal Transduct Target Ther. 2024; 9(1):274.

PMID: 39420203 PMC: 11491057. DOI: 10.1038/s41392-024-01979-x.

Engineered Mesenchymal Stem Cells as Treatment for Cancers: Opportunities, Clinical Applications and Challenges.

Shamsul Kamal A, Fakiruddin K, Bobbo K, Ling K, Vidyadaran S, Abdullah S Malays J Med Sci. 2024; 31(5):56-82.

PMID: 39416732 PMC: 11477465. DOI: 10.21315/mjms2024.31.5.5.

Editorial: Immunotherapeutic strategies to target cancer stem cells: state of the art in basic research to clinical application.

Babajani A, Naseri M, Vakhshiteh F, Ghods R, Madjd Z Front Immunol. 2024; 15:1490569.

PMID: 39376570 PMC: 11456472. DOI: 10.3389/fimmu.2024.1490569.

Bioengineered Mesenchymal Stem/Stromal Cells in Anti-Cancer Therapy: Current Trends and Future Prospects.

Gil-Chinchilla J, Zapata A, Moraleda J, Garcia-Bernal D Biomolecules. 2024; 14(7).

PMID: 39062449 PMC: 11275142. DOI: 10.3390/biom14070734.

Precision Nanomedicine with Bio-Inspired Nanosystems: Recent Trends and Challenges in Mesenchymal Stem Cells Membrane-Coated Bioengineered Nanocarriers in Targeted Nanotherapeutics.

Baig M, Ahmad A, Pathan R, Mishra R J Xenobiot. 2024; 14(3):827-872.

PMID: 39051343 PMC: 11270309. DOI: 10.3390/jox14030047.

References

Martinez-Carmona M, Lozano D, Baeza A, Colilla M, Vallet-Regi M . A novel visible light responsive nanosystem for cancer treatment. Nanoscale. 2017; 9(41):15967-15973. DOI: 10.1039/c7nr05050j. View

Dasari V, Kaur K, Velpula K, Gujrati M, Fassett D, Klopfenstein J . Upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway. PLoS One. 2010; 5(4):e10350. PMC: 2859936. DOI: 10.1371/journal.pone.0010350. View

Spaeth E, Klopp A, Dembinski J, Andreeff M, Marini F . Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther. 2008; 15(10):730-8. DOI: 10.1038/gt.2008.39. View

El-Bialy T, Alhadlaq A, Wong B, Kucharski C . Ultrasound effect on neural differentiation of gingival stem/progenitor cells. Ann Biomed Eng. 2014; 42(7):1406-12. DOI: 10.1007/s10439-014-1013-9. View

Stengel C, Newman S, Leese M, Potter B, Reed M, Purohit A . Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents. Br J Cancer. 2009; 102(2):316-24. PMC: 2816659. DOI: 10.1038/sj.bjc.6605489. View

Shukla S, Bhaskaran N, MacLennan G, Gupta S . Deregulation of FoxO3a accelerates prostate cancer progression in TRAMP mice. Prostate. 2013; 73(14):1507-17. PMC: 4018753. DOI: 10.1002/pros.22698. View

Zhang Q, Li X, Li Y, Chen S, Shen X, Dong X . Expression of the PTEN/FOXO3a/PLZF signalling pathway in pancreatic cancer and its significance in tumourigenesis and progression. Invest New Drugs. 2019; 38(2):321-328. DOI: 10.1007/s10637-019-00791-7. View

Petrella F, Cocce V, Masia C, Milani M, Omodeo Sale E, Alessandri G . Paclitaxel-releasing mesenchymal stromal cells inhibit in vitro proliferation of human mesothelioma cells. Biomed Pharmacother. 2017; 87:755-758. DOI: 10.1016/j.biopha.2017.01.118. View

Gerhardt H, Semb H . Pericytes: gatekeepers in tumour cell metastasis?. J Mol Med (Berl). 2007; 86(2):135-44. DOI: 10.1007/s00109-007-0258-2. View

10.

Seo S, Kim K, Park S, Suh Y, Kim S, Jeun S . The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. Gene Ther. 2011; 18(5):488-95. PMC: 3125103. DOI: 10.1038/gt.2010.170. View

11.

Lin J, Wang J, Chen M, Chen H, Chang T, Su B . Colon cancer mesenchymal stem cells modulate the tumorigenicity of colon cancer through interleukin 6. Exp Cell Res. 2013; 319(14):2216-29. DOI: 10.1016/j.yexcr.2013.06.003. View

12.

Rolfo A, Giuffrida D, Giuffrida M, Todros T, Calogero A . New perspectives for prostate cancer treatment: in vitro inhibition of LNCaP and PC3 cell proliferation by amnion-derived mesenchymal stromal cells conditioned media. Aging Male. 2014; 17(2):94-101. DOI: 10.3109/13685538.2014.896894. View

13.

Borisy G, Heald R, Howard J, Janke C, Musacchio A, Nogales E . Microtubules: 50 years on from the discovery of tubulin. Nat Rev Mol Cell Biol. 2016; 17(5):322-8. PMC: 5116387. DOI: 10.1038/nrm.2016.45. View

14.

Salehi H, Al-Arag S, Middendorp E, Gergely C, Cuisinier F, Orti V . Dental pulp stem cells used to deliver the anticancer drug paclitaxel. Stem Cell Res Ther. 2018; 9(1):103. PMC: 5897939. DOI: 10.1186/s13287-018-0831-3. View

15.

Bonomi A, Silini A, Vertua E, Signoroni P, Cocce V, Cavicchini L . Human amniotic mesenchymal stromal cells (hAMSCs) as potential vehicles for drug delivery in cancer therapy: an in vitro study. Stem Cell Res Ther. 2015; 6:155. PMC: 4552458. DOI: 10.1186/s13287-015-0140-z. View

16.

Pessina A, Cocce V, Pascucci L, Bonomi A, Cavicchini L, Sisto F . Mesenchymal stromal cells primed with Paclitaxel attract and kill leukaemia cells, inhibit angiogenesis and improve survival of leukaemia-bearing mice. Br J Haematol. 2013; 160(6):766-78. DOI: 10.1111/bjh.12196. View

17.

Lin H, Hu B, He X, Mao J, Wang Y, Wang J . Overcoming Taxol-resistance in A549 cells: A comprehensive strategy of targeting P-gp transporter, AKT/ERK pathways, and cytochrome P450 enzyme CYP1B1 by 4-hydroxyemodin. Biochem Pharmacol. 2019; 171:113733. DOI: 10.1016/j.bcp.2019.113733. View

18.

Fatima F, Nawaz M . Vesiculated Long Non-Coding RNAs: Offshore Packages Deciphering Trans-Regulation between Cells, Cancer Progression and Resistance to Therapies. Noncoding RNA. 2018; 3(1). PMC: 5831998. DOI: 10.3390/ncrna3010010. View

19.

Jiang X, Gao J . Exosomes as novel bio-carriers for gene and drug delivery. Int J Pharm. 2017; 521(1-2):167-175. DOI: 10.1016/j.ijpharm.2017.02.038. View

20.

Clavreul A, Pourbaghi-Masouleh M, Roger E, Lautram N, Montero-Menei C, Menei P . Human mesenchymal stromal cells as cellular drug-delivery vectors for glioblastoma therapy: a good deal?. J Exp Clin Cancer Res. 2017; 36(1):135. PMC: 5622550. DOI: 10.1186/s13046-017-0605-2. View